Onconetix appoints Ajit Singh and Thomas Meier to board of directors

Onconetix, Inc.

Ajit Singh, PhD, appointed to fill vacancy created by Neil Campbell's resignation, effective Feb 8, 2024.
Thomas Meier, PhD, also appointed; press release announced Feb 13, 2024.
Singh is partner at Artiman Ventures, former CEO of Biolmagene (acquired by Roche), ex-global CEO of Siemens Oncology.
Meier is co-founder of Santhera Pharmaceuticals, raised ~$300M, managed Raxone approval in Europe.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ajit Singh

Director

ONCO · Onconetix, Inc.

Effective: 2024-02-08
Filed: February 13, 2024, 6:59 PM ET

On February 8, 2024, the Board of Directors (the “ Board ”) of the Company appointed Ajit Singh to fill the vacancy created by the resignation of Neil Campbell.

Departed

Neil Campbell

Director

ONCO · Onconetix, Inc.

Successor: Ajit Singh
Filed: February 13, 2024, 6:59 PM ET

On February 8, 2024, the Board of Directors (the “ Board ”) of the Company appointed Ajit Singh to fill the vacancy created by the resignation of Neil Campbell.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ajit Singh was appointed as Director at Onconetix, Inc..

Action: appointed
Role: Director

Exact text from the filing

On February 8, 2024, the Board of Directors (the “ Board ”) of the Company appointed Ajit Singh to fill the vacancy created by the resignation of Neil Campbell.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Neil Campbell resigned as Director at Onconetix, Inc..

Action: resigned
Role: Director

Exact text from the filing

On February 8, 2024, the Board of Directors (the “ Board ”) of the Company appointed Ajit Singh to fill the vacancy created by the resignation of Neil Campbell.

View on SEC.gov

Onconetix, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-012876

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.